Loading clinical trials...
Loading clinical trials...
Phase II Trial of V8 in Treating Kidney Failure
Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Immunitor LLC
Ulaanbaatar, Mongolia
Start Date
June 16, 2020
Primary Completion Date
May 15, 2021
Completion Date
September 1, 2021
Last Updated
May 8, 2020
20
ESTIMATED participants
V8
BIOLOGICAL
Lead Sponsor
Immunitor LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07238374